Claims for Patent: 9,428,565

Summary for Patent: 9,428,565

Title:	Treatment and bioluminescent visualization using multimodal TRAIL molecules
Abstract:	Described herein are novel compositions comprising multimodal TRAIL agents and cells engineered to express such multimodal TRAIL agents, including cells encapsulated in a scaffold or matrix, for use in the treatment of disorders such as cancer.
Inventor(s):	Shah; Khalid (Andover, MA)
Assignee:	The General Hospital Corporation (Boston, MA)
Application Number:	13/982,343
Patent Claims:	1. A method of treatment and bioluminescent visualization for a subject having a malignant condition comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a soluble TRAIL fusion protein comprising, in the following N-terminal to C-terminal order, a reporter module, a linker module of at least 8 amino acids, and a therapeutic TRAIL module, wherein said therapeutic TRAIL module comprises an extracellular domain of human TRAIL of SEQ ID NO: 1, and a pharmaceutically acceptable carrier. 2. The method of claim 1, wherein the malignant condition is a glioblastoma. 3. The method of claim 1, further comprising administering to the subject, one or more additional chemotherapeutic agents, biologics, drugs, or treatments as part of a combinatorial therapy. 4. The method of claim 3, wherein the chemotherapeutic agent, biologic, drug, or treatment is selected from the group consisting of: radiation therapy, tumor resection surgery, gemcitabine, cisplastin, paclitaxel, carboplatin, bortezomib, AMG479, vorinostat, rituximab, temozolomide, rapamycin, ABT-737, and PI-103. 5. The method of claim 1, wherein the pharmaceutical composition is administered at a surgical site. 6. The method of claim 5, wherein the surgical site is a tumor resection site. 7. The method of claim 1, wherein the linker domain comprises the amino acid sequence of SEQ ID NO: 4. 8. The method of claim 1, wherein the therapeutic TRAIL module comprises amino acids 39-281 of SEQ ID NO: 1. 9. The method of claim 1, wherein the therapeutic TRAIL module comprises amino acids 95-281 of SEQ ID NO: 1. 10. The method of claim 1, wherein the therapeutic TRAIL module comprises amino acids 114-281 of SEQ ID NO: 1. 11. The method of claim 1, wherein the therapeutic TRAIL module consists of amino acids 114-281 of SEQ ID NO: 1. 12. The method of claim 1, wherein the soluble TRAIL fusion protein is encoded by a human stem cell comprising a nucleic acid sequence encoding the soluble TRAIL agent. 13. The method of claim 12, wherein the human stem cell is encapsulated in a matrix or scaffold.

Details for Patent 9,428,565

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2031-01-31
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2031-01-31
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2031-01-31